ESLA Estrella Immunopharma: Rasio rega marang prakiraan pendapatan

Estrella Immunopharma (ESLA) develops innovative T-cells that extend patient life and suppress relapses. The forward P/S trajectory on the GURU.Markets chart shows that the current level is . The ARTEMIS platform for combating lymphomas ensures strong pricing power. Meanwhile, the company adheres to environmental standards by controlling chemical disposal within its laboratories.

ESLA (Estrella Immunopharma, Inc.) riwayat Rasio rega marang pendapatan sing dikarepake saka 04.07.2022 nganti 15.11.2026

ESLA (estrellabio.com): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:

Rega saham estrellabio.com|ESLA - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar Estrella Bio|ESLA - Rega Tumbas Perusahaan

- indikator nilai buku ekuitas:

Nilai Akuntansi saben Saham Estrella Immunopharma|ESLA - Total Aset Bersih|Rasio Nilai Pasar marang Nilai Buku estrellabio.com|ESLA - Nilai Agregat Aset

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Estrella Immunopharma|ESLA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Estrella Immunopharma, Inc.|ESLA - Utang perusahaan|Rasio utang marang kapitalisasi buku Estrella Immunopharma, Inc.|ESLA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Estrella Immunopharma|Indikator likuiditas cepet estrellabio.com

- indikator pendapatan resik lan kelipatan nilai:

ESLA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Estrella Immunopharma|ESLA - Periode bali modal bisnis|Rega marang bathi mangsa ngarep estrellabio.com|ESLA - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Estrella Immunopharma Inc|ESLA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Estrella Immunopharma|ESLA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan estrellabio.com|ESLA - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Estrella Immunopharma

- rincian pendapatan lan dodolan emiten:

ESLA - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan Estrella Immunopharma, Inc.|ESLA - Rasio rega marang dodolan|Multiplikator Forward P/S Estrella Immunopharma Inc|ESLA - Dinamika pendapatan YoY sajrone rolas wulan kepungkur

Ringkesan analitik perusahaan:ESLA (Estrella Bio)

The forward P/S is calculated as the ratio of current market capitalization to expected annual sales volume, reflecting market expectations regarding the value of each unit of future revenue. For Estrella Immunopharma (ESLA), this indicator assesses the investment attractiveness of the ARTEMIS platform in lymphoma therapy, allowing the forward price-to-sales multiple chart to track the valuation dynamics of the company's innovative potential between quarterly reports.

Karo sapa Estrella Immunopharma saingan

TG Therapeutics - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Arcellx Therapeutics ACLX|discmedicine.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syndax.com|Kura Oncology (KURA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ADC Therapeutics Corp|FHTX (foghorntx.com) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan VOR|Multiplikator forward rega marang pendapatan NKTX (Nkarta, Inc.)|Rasio rega marang pendapatan sing dikarepake COEP|Multiplikator Forward P/S ATNM (Actinium Pharma)|CASI (CASI Pharmaceuticals, Inc) - Rega mangsa ngarep marang pendapatan|MRKR: Multiplikator forward rega marang pendapatan|INAB - Multiplikator Forward P/S|ERNA (eternatx.com) - Multiplikator forward rega marang pendapatan|GT Biopharma, Inc. - Rega forward marang dodolan|APTO (Aptose Biosciences) - Multiplikator Forward P/S|BPTH: Rega forward marang dodolan|Multiplikator Forward P/S MEIP|VINC (Vincerx Pharma) - Rega forward marang dodolan